Head to Head Survey: Calmare Therapeutics (OTCMKTS:CTTC) vs. NeuroPace (NASDAQ:NPCE)

NeuroPace (NASDAQ:NPCE) and Calmare Therapeutics (OTCMKTS:CTTC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings for NeuroPace and Calmare Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	0	1	4	0	2.80
Calmare Therapeutics	0	0	0	0	0.00

NeuroPace currently has a consensus price target of $14.80, suggesting a potential upside of 20.23%. Given NeuroPace’s stronger consensus rating and higher probable upside, equities analysts clearly believe NeuroPace is more favorable than Calmare Therapeutics.

Earnings & Valuation

This table compares NeuroPace and Calmare Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$65.42 million	5.62	-$32.96 million	($1.00)	-12.31
Calmare Therapeutics	N/A	N/A	N/A	N/A	N/A

Calmare Therapeutics has lower revenue, but higher earnings than NeuroPace.

Profitability

This table compares NeuroPace and Calmare Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroPace	-36.74%	-205.41%	-28.29%
Calmare Therapeutics	N/A	N/A	N/A

Institutional & Insider Ownership

78.8% of NeuroPace shares are held by institutional investors. 22.2% of NeuroPace shares are held by company insiders. Comparatively, 17.5% of Calmare Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

NeuroPace beats Calmare Therapeutics on 6 of the 9 factors compared between the two stocks.

About NeuroPace

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

About Calmare Therapeutics

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.